Document Detail


Duration of action of angiotensin converting enzyme inhibitors.
MedLine Citation:
PMID:  8845089     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Duration of action of an angiotensin converting enzyme (ACE) inhibitor is not solely related to its individual elimination half-life. It is also determined by its ACE inhibiting potency and affinity for ACE. Its degree of lipophilicity is also an important factor in determining tissue penetration. Any attempt to calculate the duration of action, and, consequently, the interdosing interval, of an ACE inhibitor should take into account and integrate all these variables. The measurement (or the calculation) of each of these variables is not in itself an easy task and is very much prone to error. Given the failure of pharmacokinetic and pharmacodynamic studies to provide an adequate and simple method capable of predicting reliably the time-effect relationship of ACE inhibitors, it is obvious that the pragmatic way to determine this time-effect profile is to monitor blood pressure changes during the clinical use of a given ACE inhibitor. Because very little information is available for many ACE inhibitors concerning their trough/peak ratio, we have recently reviewed all the published studies assessing the antihypertensive efficacy of commercially available ACE inhibitors with ambulatory blood pressure monitoring. Our literature analysis suggests that not all once daily ACE inhibitors comply with the Food and Drug Administration requirement of a trough/peak ratio higher than 50%. However, current evidence suggests that the definition of this ratio is dependent upon the methodology employed for its determination. The only validated analytical approach that is based on blood pressure measurements in a few confined patients, during phase II dose-finding studies. Fuller information may be sought with alternative evaluative approaches based on ambulatory BP measurements in large numbers of patients and in more pragmatic daily life conditions. Although this remains to be demonstrated, long acting ACE inhibitors may provide additional benefits over the shorter acting ones by producing an optimal 24 h and longer therapeutic coverage, with fewer peak-effect related side effects and better control of blood pressure during critical nighttime and early morning hours.
Authors:
F Zannad
Related Documents :
24917969 - Oesophageal pressure-flow metrics in relation to bolus volume, bolus consistency, and b...
10642299 - Angiotensin i-converting enzyme antisense prevents altered renal vascular reactivity, b...
87679 - Improvement of chronic congestive heart-failure by oral captopril.
2468859 - Effects of nitrendipine on blood pressure, renin-angiotensin system, and kidney functio...
20078079 - Antihypertensive effect of benifuuki tea containing o-methylated egcg.
2129469 - Antiproteinuric effect of angiotensin-converting-enzyme inhibitors in patients with pri...
8948319 - Secondary hypertension: evaluation and treatment.
1725369 - Hemodynamic effects of endothelin-1 in the newborn piglet: influence on pulmonary and s...
9707199 - Collagen organization in the branching region of human brain arteries.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of hypertension     Volume:  8     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  1995 Oct 
Date Detail:
Created Date:  1996-10-23     Completed Date:  1996-10-23     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  75S-81S     Citation Subset:  IM    
Affiliation:
University of Nancy, Hôpital Central, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Blood Pressure Monitoring, Ambulatory
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Time Factors
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Permanent blood pressure control over the 24 h by trandolapril.
Next Document:  Compliance in the treatment of hypertension. A need for action.